Literature DB >> 3935795

Rejection of syngeneic tumor cells by the interaction of Lyt-1+ T lymphocytes and macrophages.

M Mitani, T Matsumoto, K Mori, S Miake, K Himeno, K Nomoto.   

Abstract

A high degree of cytostatic activity was detected in peritoneal exudate cells (PEC) from BALB/c mice immunized with mitomycin C-treated Meth A cells (MMC-MA) given intraperitoneally (i.p.) While this cytostatic activity was not detected in a nonadherent fraction of immune PEC, the addition of starch-induced PEC to the nonadherent immune cells led to a cytostatic activity. Treatment of these nonadherent cells with anti-Thy-1 X 2 or anti-Lyt-1 X 2 antibody plus complement abolished the restored cytostatic activity. Normal PEC were also rendered cytostatic after addition of the culture supernate of a nonadherent fraction of immune PEC mixed with MMC-MA. These findings suggest that macrophages are rendered cytostatic by immunization with tumor antigen and that these cytostatic macrophages evolve after activation of sensitized Lyt-1 positive T lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3935795

Source DB:  PubMed          Journal:  J Clin Lab Immunol        ISSN: 0141-2760


  3 in total

1.  In situ activation of syngeneic tumour-specific cytotoxic T lymphocytes: intra-pinna immunization followed by restimulation in the peritoneal cavity.

Authors:  V Schirrmacher; S Leidig; A Griesbach
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

2.  Characterization of variant and parental-cross-protective immunity to immunogenic variants of a murine fibrosarcoma using the local adoptive transfer assay.

Authors:  W Simcik; T L Sheu; S J LeGrue
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  Analysis of effector T cells against the murine syngeneic tumor MethA in mice orally administered antitumor polysaccharide SPR-901.

Authors:  Y Takeda; M Tanaka; H Miyazaki; S Takeo; K Nomoto; Y Yoshikai
Journal:  Cancer Immunol Immunother       Date:  1994-03       Impact factor: 6.968

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.